Abstract
The list of therapeutic options for male erectile dysfunction continues to expand. Notably, 2 new oral therapies have entered clinical trials. However, preliminary results suggest that neither phentolamine nor apomorphine pose an immediate threat to sildenafil’s pre-eminent position as first-line therapy. Nevertheless, emergence of new agents will provide more options, especially for men who do not respond to sildenafil or for whom the agent is contraindicated. However, continued evaluation of intraurethral alprostadil has yielded disappointing results, as reported at the American Urological Association (AUA) meeting [ San Diego, US; June 1998 ].
Rights and permissions
About this article
Cite this article
Bankhead, C. Competition mounts but ‘Viagra’ stays on top. Inpharma Wkly. 1149, 11–12 (1998). https://doi.org/10.2165/00128413-199811490-00024
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-199811490-00024